Evidence map›Paper›PMID 42638746›Full record

ArticleFrontiers in pediatrics2026

Translational insights into manufacturability and stability of broadly neutralizing antibodies for pediatric HIV prevention: lessons from plant-produced CAP256-VRC26.25.

Tsepo L Tsekoa, Lusisizwe Kwezi, Priyen Pillay, Sibongile Mtimka, Maabo Moralo, Kabamba Alexandre, Joseph Nkolola, Dan H Barouch, Rachel Chikwamba

Abstract read
In one paragraph

Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tsepo L TsekoaFuture Production: Chemicals Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.
Lusisizwe KweziFuture Production: Chemicals Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.
Priyen PillayFuture Production: Chemicals Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.
Sibongile MtimkaFuture Production: Chemicals Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.
Maabo MoraloFuture Production: Chemicals Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.
Kabamba AlexandreFuture Production: Chemicals Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.
Joseph NkololaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Rachel ChikwambaFuture Production: Chemicals Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies hold significant promise for preventing HIV infection in infants and children. However, global access remains constrained by the high production costs and infrastructure requirements associated with complex mammalian cell manufacturing platforms. Alternative expression systems, including plant-based production, have been proposed as scalable and potentially lower-cost approaches for antibody manufacturing. Here, we evaluated the

Indexed as

antibody manufacturabilitybroadly neutralizing antibodieshiv preventionpharmacokineticsplant molecular farming

Identifiers

PMID42638746
PMCPMC13500764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.